Neuroprotective Effect of Remote Ischemic Conditioning on Patients Undergoing Intravenous Thrombolysis: A Randomized Controlled Trial

Abstract

Intravenous thrombolysis (IVT) is the treatment with the highest level of evidence for acute ischemic stroke, but about half of patients fail to achieve a favorable prognosis. This study (NCT05598658) proposed a treatment strategy of adjunctive two sessions of remote ischemic conditioning (RIC) within 24 h after IVT, and evaluated the effects through cerebral autoregulation (CA) and brain-injury biomarkers. Patients were randomized (1:1) to the RIC or sham-RIC groups, which received 200 and 60 mmHg RIC, respectively, at 6 and 18–24 h after IVT. CA was assessed at 2 and 7 days after IVT and serum brain-injury biomarkers were evaluated at 24 h after IVT. The primary outcome was CA at 2 days after IVT. A total of 100 patients were randomized to the RIC or sham-RIC group. Ipsilateral CA was significantly higher in the RIC group than in the sham-RIC group at 2 days (β: 14.970 [95% confidence interval, 7.741–22.199; p < 0.001]) and 7 days after IVT. Simultaneously, neuron-specific enolase level at 24 h after IVT was significantly lower in the RIC than the sham-RIC group. These results suggest that adjunctive two sessions of RIC within 24 h after IVT can effectively exert neuroprotective effects in patients with IVT.

Keywords

brain injury biomarker / cerebral autoregulation / intravenous thrombolysis / neuron-specific enolase / remote ischemic conditioning

References

[1] S. S. Martin, A. W. Aday, Z. I. Almarzooq, et al., “2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association,” Circulation 149, no. 8 (2024): e347–e913.

[2] V. L. Feigin, B. A. Stark, C. O. Johnson, et al., “Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” Lancet Neurology 20, no. 10 (2021): 795–820.

[3] N. Yang, H. Lee, and C. Wu, “Intravenous Thrombolysis for Acute Ischemic Stroke: From Alteplase to Tenecteplase,” Brain Circulation 9, no. 2 (2023): 61–63.

[4] N. Logallo, V. Novotny, J. Assmus, et al., “Tenecteplase Versus Alteplase for Management of Acute Ischaemic Stroke (NOR-TEST): A Phase 3, Randomised, Open-Label, Blinded Endpoint Trial,” Lancet Neurology 16, no. 10 (2017): 781–788.

[5] H. Zhao, Y. Meng, S. Li, G. Liu, and X. Ji, “A Novel Perspective in Stroke Neuroprotection: Leveraging Hypoxic Pocket Insights for Studying Preconditioning and Postconditioning,” Neuroprotection 2, no. 4 (2024): 288–295.

[6] A. J. Ripley, M. S. Jeffers, M. W. McDonald, et al., “Neuroprotection by Remote Ischemic Conditioning in Rodent Models of Focal Ischemia: A Systematic Review and Meta-Analysis,” Translational Stroke Research 12, no. 3 (2021): 461–473.

[7] Q. He, Y. Ma, C. Fang, et al., “Remote Ischemic Conditioning Attenuates Blood-Brain Barrier Disruption After Recombinant Tissue Plasminogen Activator Treatment via Reducing PDGF-CC,” Pharmacological Research 187 (2023): 106641.

[8] M. N. Hoda, K. Bhatia, S. S. Hafez, et al., “Remote Ischemic Perconditioning Is Effective After Embolic Stroke in Ovariectomized Female Mice,” Translational Stroke Research 5, no. 4 (2014): 484–490.

[9] M. N. Hoda, S. Siddiqui, S. Herberg, et al., “Remote Ischemic Perconditioning Is Effective Alone and in Combination With Intravenous Tissue-Type Plasminogen Activator in Murine Model of Embolic Stroke,” Stroke; A Journal of Cerebral Circulation 43, no. 10 (2012): 2794–2799.

[10] H. S. Chen, Y. Cui, X. Q. Li, et al., “Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial,” JAMA 328, no. 7 (2022): 627–636.

[11] Y. D. He, Z. N. Guo, C. Qin, et al., “Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke,” Annals of Clinical and Translational Neurology 7, no. 6 (2020): 972–979.

[12] J. Q. An, Y. W. Cheng, Y. C. Guo, et al., “Safety and Efficacy of Remote Ischemic Postconditioning After Thrombolysis in Patients With Stroke,” Neurology 95, no. 24 (2020): e3355–e3363.

[13] K. D. Hougaard, N. Hjort, D. Zeidler, et al., “Remote Ischemic Perconditioning as an Adjunct Therapy to Thrombolysis in Patients With Acute Ischemic Stroke: A Randomized Trial,” Stroke; A Journal of Cerebral Circulation 45, no. 1 (2014): 159–167.

[14] S. Tiedt, A. M. Buchan, M. Dichgans, I. Lizasoain, M. A. Moro, and E. H. Lo, “The Neurovascular Unit and Systemic Biology in Stroke—Implications for Translation and Treatment,” Nature Reviews Neurology 18, no. 10 (2022): 597–612.

[15] Q. Liu, C. Wu, M. Fisher, D. Wu, and X. Ji, “Molecular Windows for Ischemic Stroke Treatment,” Science Bulletin 70, no. 17 (2025): 2714–2716.

[16] D. G. MacGregor, H. V. Carswell, D. I. Graham, J. McCulloch, and I. M. Macrae, “Impaired Cerebral Autoregulation 24 h After Induction of Transient Unilateral Focal Ischaemia in the Rat,” European Journal of Neuroscience 12, no. 1 (2000): 58–66.

[17] J. L. Fan, T. O'Donnell, J. Lanford, et al., “Dietary Nitrate Reduces Blood Pressure and Cerebral Artery Velocity Fluctuations and Improves Cerebral Autoregulation in Transient Ischemic Attack Patients,” Journal of Applied Physiology 129, no. 3 (2020): 547–557.

[18] R. L. K. Aaslid, W. Sorteberg, and H. Nornes, “Cerebral Autoregulation Dynamics in Humans,” Stroke; A Journal of Cerebral Circulation 20, no. 1 (1989): 45–52.

[19] Z. N. Guo, W. T. Guo, J. Liu, et al., “Changes in Cerebral Autoregulation and Blood Biomarkers After Remote Ischemic Preconditioning,” Neurology 93, no. 1 (2019): e8–e19.

[20] A. S. M. Salinet, R. B. Panerai, and T. G. Robinson, “The Longitudinal Evolution of Cerebral Blood Flow Regulation After Acute Ischaemic Stroke,” Cerebrovascular Diseases Extra 4, no. 2 (2014): 186–197.

[21] L. Xiong, X. Liu, T. Shang, et al., “Impaired Cerebral Autoregulation: Measurement and Application to Stroke,” Journal of Neurology, Neurosurgery, and Psychiatry 88, no. 6 (2017): 520–531.

[22] H. Chen, Y. He, S. Chen, S. Qi, and J. Shen, “Therapeutic Targets of Oxidative/Nitrosative Stress and Neuroinflammation in Ischemic Stroke: Applications for Natural Product Efficacy With Omics and Systemic Biology,” Pharmacological Research 158 (2020): 104877.

[23] Y. Y. Sun, H. J. Zhu, R. Y. Zhao, et al., “Remote Ischemic Conditioning Attenuates Oxidative Stress and Inflammation via the Nrf2/HO-1 Pathway in MCAO Mice,” Redox Biology 66 (2023): 102852.

[24] L. Wang, C. Ren, Y. Li, et al., “Remote Ischemic Conditioning Enhances Oxygen Supply to Ischemic Brain Tissue in a Mouse Model of Stroke: Role of Elevated 2,3-Biphosphoglycerate in Erythrocytes,” Journal of Cerebral Blood Flow and Metabolism 41, no. 6 (2021): 1277–1290.

[25] M. Herrmann, P. Vos, M. T. Wunderlich, C. H. de Bruijn, and K. J. Lamers, “Release of Glial Tissue-Specific Proteins After Acute Stroke: A Comparative Analysis of Serum Concentrations of Protein S-100B and Glial Fibrillary Acidic Protein,” Stroke; A Journal of Cerebral Circulation 31, no. 11 (2000): 2670–2677.

[26] Z. N. Guo, R. Abuduxukuer, P. Zhang, et al., “Safety and Efficacy of Remote Ischemic Conditioning in Patients with Intravenous Thrombolysis: The SERIC-IVT Trial,” Stroke; A Journal of Cerebral Circulation 56, no. 2 (2025): 335–343.

[27] W. J. Powers, A. A. Rabinstein, T. Ackerson, et al., “Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,” Stroke; A Journal of Cerebral Circulation 50, no. 12 (2019): e344–e418.

[28] W. Hacke, M. Kaste, C. Fieschi, et al., “Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. The European Cooperative Acute Stroke Study (ECASS),” JAMA 274, no. 13 (1995): 1017–1025.

[29] C. Hou, J. Lan, Y. Lin, et al., “Chronic Remote Ischaemic Conditioning in Patients With Symptomatic Intracranial Atherosclerotic Stenosis (the RICA trial): A Multicentre, Randomised, Double-Blind Sham-Controlled Trial in China,” Lancet Neurology 21, no. 12 (2022): 1089–1098.

[30] Z.-N. Guo, R. Abuduxukuer, P. Zhang, C. Wang, and Y. Yang, “Safety and Efficacy of Remote Ischemic Conditioning Combined With Endovascular Thrombectomy for Acute Ischemic Stroke due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-Controlled Clinical Trial (SERIC-EVT): Study Protocol,” International Journal of Stroke 18, no. 4 (2022): 484–489.

[31] R. B. Panerai, “Cerebral Autoregulation: From Models to Clinical Applications,” Cardiovascular Engineering 8, no. 1 (2008): 42–59.

[32] J. A. Claassen, A. S. Meel-van den Abeelen, D. M. Simpson, and R. B. Panerai, International Cerebral Autoregulation Research Network, “Transfer Function Analysis of Dynamic Cerebral Autoregulation: A White Paper from the International Cerebral Autoregulation Research Network,” Journal of Cerebral Blood Flow and Metabolism 36, no. 4 (2016): 665–680.

[33] Z. Han, W. Zhao, H. Lee, et al., “Remote Ischemic Conditioning With Exercise (RICE)-Rehabilitative Strategy in Patients With Acute Ischemic Stroke: Rationale, Design, and Protocol for a Randomized Controlled Study,” Frontiers in Neurology 12 (2021): 654669.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.